Objectives: Psychostimulants are highly addictive and their use is increasing. Little is known about psychostimulant-related deaths. This study identified characteristics, risk factors, and contributing substances reported upon death among former prison inmates who died from a psychostimulant-related death. Methods: This retrospective cohort study of released inmates from 1999 to 2003 (N = 30,237) linked data from the Washington State Department of Corrections with the National Death Index. We examined characteristics of individuals who died with psychostimulants listed among their causes of death. These were categorized into 3 groups: (1) noncocaine psychostimulants, (2) cocaine only, and (3) all psychostimulants. Cox proportional hazards regression determined risk factors for death in each group, and the risk of death in the first 2 weeks after release from prison Results: Of the 443 inmates who died, 25 (6%) had noncocaine psychostimulants listed among their causes of death. Six of these 25 deaths had both noncocaine psychostimulants and cocaine listed among their causes-of-death. Most of the former inmates who died with noncocaine psychostimulants were male (n = 21, 84%) and nonHispanic white (88%, n = 22). Cocaine only was listed among the causes-of-death for 49 former inmates; most were male (n = 35, 71%) and non-Hispanic white (n = 27, 55%). Longer length of incarceration was associated with a reduced risk of death from any psychostimulant use (hazard ratio = 0.76, confidence interval = 0.63-0.920 for each additional year of incarceration) and from use of noncocaine psychostimulants (hazard ratio = 0.42, 95% CI = 0. 22-0.80 of death was highest during the first 2 weeks postrelease for cocaine only-related deaths (incidence mortality ratio = 1224.0, confidence interval = 583-1865). Conclusions: Former prisoners have a significant risk of death from psychostimulants, especially within the first 2 weeks postrelease.
M
ethamphetamine, cocaine, and other psychostimulants are highly addictive. Their use is increasing across the United States, impacting the criminal justice system through psychostimulant-related crimes. Although cocaine is traditionally viewed as the most widely abused psychostimulant, methamphetamine abuse exploded in the Western United States in the late 1990s and continues to be a rampant problem (Reding, 2009 ). In 2007, 1.3 million people aged 12 years or older had used methamphetamine in the past year (SAMHSA-TEDS, 2007) . It is inexpensive, easily available, and can be manufactured from pseudoephedrine, an ingredient found in cold decongestants (U.S. Drug Enforcement Administration, 2010) . Because of its relatively low cost and potent effects, methamphetamine has emerged as a widely abused drug, especially in the Northwest (NEDTAC, 1998; Hunt, 2006) . Other psychostimulants include methylenedioxymethamphetamine, also known as ecstasy, methylphenidate (Ritalin), and dextroamphetamine (Adderall). The latter 2 drugs are used in treating attention-deficit/hyperactivity disorder (ADHD) and are also increasingly abused (DeSantis and Webb, 2008; Dupont et al., 2008; Kaye et al., 2009; Klein-Schwartz, 2002; Schifano, [AQ1] 2004; Schifano et al., 2006; Schifano et al., 2010) . Nonmedical use of prescription stimulants has been shown to be associated with concurrent illicit polydrug use (Arria et al., 2008) .
[AQ2]
Methamphetamine can cause health problems including seizures, cardiac arrhythmias, respiratory failure, brain hemorrhage, and death (Darke et al., 2008) . Case reports and population-based studies support a cause-effect relationship between methamphetamine and fatal damage to the cardiovascular, pulmonary, and neurovascular systems (Bashour, 1994; Costa et al., 2001; Farnsworth et al., 1997; Ho et al., 2009; Maury et al., 1999; McGee et al., 2004; McIntosh et al, 2006; Nestor et al., 1989 , Ohta et al., 2005 Packe et al., 1990; Westover et al., 2007; Westover et al., 2008) . Previous work has been done on cocaine overdose including medical management and death from poisoning (Alaraj et al., 2010; Schwartz et al., 2010; Wood et al., 2009; Xue et al., 2011) . Excluding cocaine, little is known about psychostimulant overdose, including the epidemiology of fatal poisoning. Therefore, the focus of the study is to provide new, descriptive information about noncocaine psychostimulant-related deaths and to compare them to cocaine only-related deaths using a unique cohort of former inmates released from prison followed to death.
The number of adults in the correctional population in the United States is increasing. In 2008, more than 7.3 million people were on probation, incarcerated, or on parole (Blaze and Bonczar, 2009 ). Methamphetamine-related crimes rose 4% to 7% from 1997 to 2004 according to the Bureau of Justice Statistics. In 2005, 20% of all drug offenders sentenced in US District Court were due to methamphetamine-related drug offenses (Mumola and Karberg, 2006) .
As the US population of former inmates grows, society faces another set of difficulties. People released from incarceration often have a difficult time integrating back into society and engage in risky behavior, such as illicit drug use, which can result in an untimely death (Farrell and Marsden, 2008; Harding-Pink, 1990 Kariminia et al., 2007 . A prior study in the northwestern United States demonstrated an increased risk of death among former inmates, especially during the first 2 weeks postrelease (Binswanger et al., 2007) . Many of these [AQ3] deaths were attributed to psychostimulants including cocaine and methamphetamine. This study aims to better understand contributing substances and associated health conditions upon death, sociodemographic risk factors, and incarceration risk factors for psychostimulant-related deaths.
METHODS
For this retrospective cohort study, we used data from a study of former inmates, which included individuals released from the Washington State Department of Corrections (DOC) between July 1, 1999, and December 31, 2003 . Of the 30,636 inmates released during the study period, 399 (1%) were excluded from the analysis using previously described exclusion criteria (Binswanger et al., 2007) . The final sample consisted of 30,237 former inmates.
Sources of Data
The data were obtained from a retrospective cohort study (Binswanger et al., 2007) , which concluded that former inmates released from the Washington State DOC were at a high risk of death after release from prison, especially death related to overdose. The original data set included linkage data from the Washington State DOC with the National Death Index (NDI), which indexes deaths in the United States as well as the District of Columbia, the Virgin Islands, and Puerto Rico (National Death Index, 2000) . The Washington State DOC provided personal identifiers for all persons released from prison during the study period. These identifiers were linked to the NDI, a computerized database of information abstracted by states from death certificates, using previously described methods (Binswanger et al., 2007) . The NDI Plus allowed us to determine the underlying and multiple causes-of-death for each deceased former inmate as they translate medical codes listed on death certificates into International Classification of Disease codes, or ICD codes (World Health Organization, 2010) . Most cases of death involving drug overdose are certified by a coroner. Many public health and substance dependence studies have used similar methods to link specific databases with NDI to determine cause-of-death information (Bell et al., 2009; Degenhardt et al., 2009; French et al., 2009; Ravndal et al., 2010; Vlahov et al., 2008) .
We performed a search of all decedents for the ICD-10 code T43.6, "poisoning by psychostimulants with abuse potential, excluding cocaine." This code was provided by the NDI on the basis of the descriptions listed by the coroner or physician upon death. T43.6 is listed as one of the multiple causes of death because poisoning (overdose) deaths cannot be listed as an underlying cause-of-death. To determine the underlying cause of death, we used the ICD-10 cause-of-death recode set 358. This recode set was established by the National Center for Health Statistics for the purposes of publishing data on causes-of-death from 1999 and beyond. Nineteen of the 25 total deaths because of noncocaine psychostimulant-related deaths were associated with the underlying cause of death codes for "accidental poisoning by and exposure to drugs and other biological substances" (code 440) or "poisoning by and exposure to drugs and biological substances of undetermined intent" (code 443). Six additional deaths were associated with other underlying causes of death (F15.2, I25, I11.9, Y11, and Y14; Table 1 ).
[T1] We also examined cocaine only-related death by performing the analogous search using the ICD code T40.5, "poisoning by cocaine." There were 55 total deaths related to poisoning by cocaine (Table 2) . Six deaths had both T40.5 and [T2] T43.6 listed among their causes of death, meaning that upon death, they had both cocaine and another psychostimulant in their system. These deaths were included in the group of 25 inmates who died from psychostimulants (described earlier), and thus excluded from our final group of 49 inmates who died with cocaine only. The original study listed 50 deaths with an underlying cause of death of overdose who had cocaine also listed among their multiple causes of death. These 50 deaths were not exclusive for cocaine and included some deaths, which included stimulants other than cocaine in their system upon death (Binswanger et al., 2007) .
We examined demographics among our 2 study groups (noncocaine psychostimulant-related deaths and cocaine only-related deaths) compared with the total study population (N = 30,237). We tabulated causes of death of interest including the underlying cause of death listed as contributors to death for both noncocaine psychostimulant-related deaths and cocaine only-related deaths. Among those who died with noncocaine psychostimulants, we examined polydrug abuse, as well as a concurrent diagnosis of mental/behavioral disorders because of the use of multiple drugs.
Statistical Methods
The primary aim is to compare persons whose death was related to psychostimulants to those who did not over variable time at risk. Cox proportional-hazards regression examined whether certain factors were related to survival time. All 30,237 subjects are included in the analyses. The data are right-censored as data on subjects were only obtained through December 31, 2003, resulting in the majority of subjects not experiencing the outcome of death. Three separate analyses examined the risk factors for 3 specific types of death: noncocaine psychostimulant-related deaths (N = 25), cocaine only-related deaths (N = 49), and the combination of death related to either noncocaine psychostimulant use or cocaine use (N = 74). Risk factors tested were the demographic variables sex, race, age, type of release, and length of incarceration (expressed in years). Race was dichotomized into 2 groups (white and nonwhite) because some of the race categories did not contain any death events, making the estimation of a hazard ratio for such race categories futile. Otherwise, race and ethnicity were combined to create the following mutually exclusive groups: Latino, non-Latino white, non-Latino African American, non-Latino American Indian/Eskimo/Aleutian, non-Latino Asian/Pacific Islander, and other. Groups that include multiple races were combined into "other" because of small numbers of deaths in this category.
Data on potential risk factors for death came from the electronic administrative records of the DOC. Generally, race and ethnicity were self-reported upon intake. Age is analyzed in decade units to facilitate easier interpretation of the resultant hazard ratios. Release status was categorized as release into the community under supervision of community custody staff ("community supervision") or release into the community without any custody supervision ("without community supervision"). Community supervision is also known as parole. We generated hazard ratios (HRs) and 95% confidence intervals (CIs). Analysis was conducted using Stata 10.1 (College Station, Texas) and SAS 9.2 (SAS Institute Inc, Cary, North Carolina).
To assess the risk of death during each 2-week interval, we calculated incident mortality rates (IMR) for each interval, defined as deaths occurring in the given interval per 100,000 person-years of risk. The exact number of days at risk in the interval for each subject was calculated, then summed over the cohort of subjects and divided by 365.25 to find the total number of years at risk. The number of deaths was divided by the years at risk, then multiplied by 100,000 to give the estimated IMR.
It is assumed that the number of deaths, X, follows a Poisson (λ) distribution, where λ is estimated on the basis of the observed data. To estimate the CI for the IMR, we used large-sample methods for the situations where the number of events is at least 10, for which it is reasonable to assume that the normal approximation to the Poisson distribution holds. Recalling that the mean and variance for X are both λ, we first calculate the 95% CI for λ for the observed years at risk as X ± z 1 − α/2 √ X, we then simply rescale this to give the 95% CI for the number of deaths per 100,000 person years at risk. When the number of deaths is less than 10, it is not reasonable to assume that the normal approximation to the Poisson distribution holds. In these situations, we used exact methods, first obtaining the 95% CI for the expectation of a Poisson variable given the observed number of deaths from a table, then again rescaling this to obtain the 95% CI for the IMR per 100,000 person years at risk.
RESULTS

Noncocaine Psychostimulant-Related Deaths
Of the 30,237 persons released from Washington State DOC, 443 died during a mean follow-up period of 1.9 years. Twenty-five (6%) of the 443 inmates had noncocaine psychostimulants (ICD-10 T43.6) listed as a condition contributing to death (Table 3) noncocaine psychostimulants listed among their causes of death were male and 21 (88%) were non-Hispanic white. The mean age at time of release was 35.9 years and the mean number of releases was 1.28. The mean length of stay in prison was significantly shorter for those inmates who died with noncocaine psychostimulants compared with the overall prison population (0.67 years vs 1.72 years). Among those who died with noncocaine psychostimulants, the mean years to death postrelease was 1.08 years compared with 1.17 years in the full cohort. Most deaths occurred in Washington State (n = 22, 88%), as in the overall population (n = 379, 86%).
Cocaine Only-Related Deaths
There were 49 inmates who died with cocaine listed as a condition of death in the absence of other noncocaine psychostimulants (Table 3) . Seventy-one percent were male (n = 35) and the majority were non-Hispanic white (55%, n = 27). The mean length of prison stay for those who died with cocaine was shorter than the total prison population (1.30 years vs 1.72 years). The mean time to death post release was much shorter for those who died with cocaine as compared with the large inmate population (0.68 years vs 1.17 years). Similar to the other groups, 94% of the inmates who died with cocaine died in Washington.
Characteristics and Causes of Death
Of the 25 former inmates who died with noncocaine psychostimulants, 22 had overdose (poisoning) listed as the primary cause of death (Table 1) . Overdose was defined as "accidental" or "of undetermined intent." "Accidental" poisonings accounted for 19 (76%) all of the psychostimulant-related deaths. Most of the former inmates who died with cocaine only had overdose (n = 45) as the underlying cause of death.
The physiologic outcomes for the 25 inmates who died with noncocaine psychostimulants are reported in Table 2 . Trends existed among the additional causes of death listings. More than half (52%, n = 13), had 3 or more drug types listed among the contributors of death, such as alcohol, cocaine, and/or heroin. Alcohol was listed as an additional condition of death in 4 noncocaine psychostimulant-related deaths. Mental/behavioral disorder because of the use of substances was another frequent condition of death (n = 12).
Trends for Increased Risk of Death
Men were less likely to die from a cocaine only-related death as compared with women (HR = 0.41, CI = 0.22-0.77; Table 4 ). A similar pattern was observed when the noncocaine [T4] psychostimulant-related deaths and the cocaine only-related deaths were combined (n = 74, HR 0.55, CI 0.32-0.94). Increasing age was associated with increased risk of death for both the cocaine only-related deaths (HR = 1.70, CI = 1.31-2.21 for each decade increase in age) and the combination of cocaine and noncocaine psychostimulant-related deaths (HR 1.59, CI = 1.28-1.98). Increased length of incarceration was associated with a decreased risk of death from noncocaine psychostimulants (HR 0.42, CI = 0.22-0.80 for each increasing year of incarceration) and for the combined groups of cocaine-only deaths and noncocaine psychostimulant deaths (all psychostimulants) (HR = 0.76, CI = 0.63-0.92).
Time of Release to Death
For all 3 groups examined, noncocaine psychostimulantrelated deaths, cocaine only-related deaths, and all-cause mortality, the incidence mortality rate (IMR) was the highest during the first 2 weeks postprison release (Table 5). The  [T5] proportion of all-cause deaths occurring in the first 2 weeks was 38/(9%), whereas for cocaine deaths, 14/49 (29%) died
in the first 2 weeks, and for noncocaine stimulants, 20% of the deaths occurred in the first 2 weeks. Of the noncocaine
psychostimulant-related deaths, 5 of the 25 total deaths occurred in the first 2 weeks postprison discharge (IMR = 437.1, CI 142-1020).
DISCUSSION
We found that psychostimulants, including cocaine, were important contributors to drug-related mortality in former inmates. Seventeen percent of deaths among former inmates had noncocaine psychostimulants (T43.6) or cocaine (T40.5) listed as a contributor to death. A systematic review of the literature showed that prevalence estimates of drug abuse and dependence in male prisoners upon reception into custody is 10% to 48% in male prisoners and 30% to 60% in female prisoners (Fazel et al., 2006) . These finding show that substance abuse and dependence is significantly more prevalent in the prison population as compared with the general population.
The vast majority of deaths in our study occurred in men. However, women who used cocaine had a higher risk of death than males. This was also seen among the combined cocaineonly and noncocaine psychostimulant-associated deaths (all psychostimulant-related deaths). Male gender was not statistically significant in regards to an increased risk of death among those who died from a noncocaine psychostimulant-related death. These findings are in contrast to national death rates related to noncocaine psychostimulants. According to the CDC Wonder Database, a national database that provides cause-ofdeath data for all deaths in the United States, during 1999 to . However, 2 previous studies have reported a higher, but not statistically significant, standardized mortality ratio (SMR) in women versus men who abuse amphetamine/methamphetamine. The first study showed increased mortality for females (SMR = 6.22, CI = 4.59-8.25) who were dependent on amphetamine versus males (SMR = 5.87, CI = 4.13-8.09) (Lejckova and Mravcik, 2007) . A second study examining mortality among methamphetamine dependent users had similar findings. Mortality was higher among females (SMR = 8.69, SE = 0.53) versus males (SMR = 5.85, SE = 2.11) (Kuo et al., 2010) .
[AQ7]
The majority of deaths related to psychostimulants were seen in non-Hispanic white males, which reflects use patterns in the United States (Ititani et al., 2007) . Nonwhite race was not protective for a death related to noncocaine psychostimulants, but did show a trend in that direction.
[AQ8]
Two of the most commonly reported cooccurring diagnoses upon death among those who died with noncocaine psychostimulants were mental disorders because of the use of drugs and accidental overdose. Psychosis, depression, and anxiety disorders have been reported with use of methamphetamine (Glasner-Edwards et al., 2009; Salo et al., 2010; Yen et al., 2006) . It is possible that when a former inmate is [AQ9] released from prison, he is more vulnerable to the effects of the drug, and has an increased risk of developing a substancerelated mental disorder. Alternatively, ex-inmates with mental disorders likely have more severe drug use diatheses. Increased vigilance may be needed if a former inmate with a known substance abuse history shows signs of a mental disorder during the post discharge period.
The other commonly reported cooccurring cause of death among those who died with noncocaine psychostimulants was accidental drug overdose, or overdose of undetermined intent. This finding was also observed to be a common cooccurring cause of death among those who died with cocaine only. Former inmates show a highest risk of death 1 to 2 weeks postprison discharge. The excess rates of acute drug-related mortality observed in the initial postrelease period among former inmates is thought to be due to many factors. Two important contributors to death include decreased drug tolerance after an extended period of abstinence and the concurrent use of multiple drugs (Møller et al., 2010; O'Neil et al., 2006) . These findings are reported more commonly among opioid users and their applicability to stimulant users remains unclear. Inmates likely engage in high risk behavior immediately postdischarge, which increases their risk of death. Over an 8-week period postprison discharge, risk of death stabilizes. Longer length of stay in prison was found to be protective in 2 outcome measures: noncocaine psychostimulantrelated deaths and the combined groups of noncocaine psychostimulant-related deaths and cocaine only-related deaths. In the cocaine only-related deaths, an increased prison stay was not found to be significantly protective, but the trend was toward this effect. This association has been observed for overdose deaths of all types in the original cohort (Binswanger et al., 2011) . This protective finding may be related to drug rehabilitation programs offered to inmates incarcerated in the Washington State DOC. In Washington, offenders are screened for addiction and given substance abuse treatment, including long-term treatment, known as a therapeutic community (TC), which lasts from 6 to 12 months in a structured, residential setting. Outpatient treatment is offered to former inmates and provides a minimum of 3 months of transitional care at designated community-based sites. According to Washington DOC, approximately 85% of offenders complete treatment through the TC program, 90% complete intensive outpatient treatment, and 67% complete outpatient treatment in the community (Patty Noble-Desy, Washington DOC). It is not clear whether this finding would be observed in other states with less access to treatment. Further study is needed to determine if resources dedicated to identifying and treating substance abusing inmates may reduce the risk of death among inmates. One can further speculate whether longer sentences allow healing of prior health effects of psychostimulants, especially development of collateral coronary circulation, or lower tolerance among subjects who have completed longer sentences allows access to euphoria at lower dose of the drug.
Further research is needed on the mechanism by which psychostimulants result in death and whether it differs by type of psychostimulant used. There appear to be multiple mechanisms by which methamphetamine causes death and our study population reflects a few them, specifically neurovascular and cardiovascular pathology (Table 2) . Acute coronary syndrome causing myocardial infarction from amphetamine/methamphetamine is described in the literature (Bashour, 1994; Costa et al., 2001; Farnsworth et al., 1997; Packe et al., 1990; Turnipseed et al., 2003; Westover et al., 2008) . Methamphetamine-associated cardiomyopathy and decompensated heart failure have also been described (Diercks et al., 2007; Diercks et al., 2008 Kaye et al, 2007 Wijetunga [AQ10] Yeo et al., 2007) , along with ischemic strokes, artery dissections, and hemorrhagic strokes. (Ho et al., 2009; McGee et al., 2004; McIntosh et al., 2006; Ohta et al., 2005; Westover et al., 2007) . Methamphetamine has also been shown to cause pulmonary complications, notably acute pulmonary edema (Maury et al., 1999; Nestor et al., 1989) . ICD-10 codes were limited in their ability to provide a more refined pathologic mechanism of psychostimulant-related cause of death.
Multiple drugs reported as contributing causes of death was a common finding in our study. Fifty-two percent of the former inmates who died with noncocaine psychostimulants listed as a cause of death had 3 or more drug types listed among the contributors to death. Polysubstance abuse makes it difficult to determine whether the pychostimulant was a proximate cause of death, a key interaction drug potentiating the effects of other drugs simultaneously abused, or just an epiphenomenon. According to the Surveillance for the National Vital Statistics Reports, the number of overdose deaths from cocaine has risen from 1999 to 2007 (3000 deaths in 1999 and 5000 in 2007). In contrast, deaths from heroin overdose have remained steady, about 1700 in 1999 and 1900 in 2007, possibly because of the implementation of naloxone training programs in heroin users (Centers for Disease Control and Prevention, 2010; Tobin et al., 2009) . A better understanding of the physiologic mechanism of psychostimulant-related deaths would permit the development of preventive therapies, antidotes, or appropriate medical management of psychostimulant-related toxicity. Unlike opioids, in which naloxone can reverse toxicity, there is no known antidote for cocaine or methamphetamine toxicity.
Our study was limited by the ambiguity of the ICD-10 code T43.6. Psychostimulants of abuse can refer to methamphetamine, amphetamine, MDMA, methylphenidates, and ephedrine. In our study population, psychostimulants most likely referred to methamphetamine; its abuse is on the rise and is more prevalent than other psychostimulants across the Northwest. To better understand methamphetamine-related morbidity and mortality, a specific ICD code should be created to distinguish methamphetamine from other psychostimulants currently listed as drugs of abuse under the T43.6 code.
We do not know specifically how many of the 25 former inmates' deaths were certified by a coroner versus a physician. This represents a limitation, which may have led to underascertainment of psychostimulant-related deaths. Suicides, homicides, overdoses, and people who are found dead outside of the hospital generally go to the coroner for a full investigation. When a person dies in a hospital of a known medical cause, an investigation is not necessarily done, and additional causes of death may be missed, biasing our results toward the null. For instance, former inmates may have had cardiac disease secondary to methamphetamine abuse hastening a death from heart failure. Methamphetamine may not be in their system at death, but was a major contributor to death. Methamphetamine may have been used by the perpetrators of violence against former inmates who died of homicide (or from motor vehicle accidents). The conditions listed on a death certificate do not define mechanism of death by psychostimulants, but provide information, which may lead to a better understanding of the mechanism of death. Our results may not be generalizable to areas of the country where methamphetamine abuse is less common (eg, East Coast), nor may it apply to deaths among individuals not recently released from prison. However, as methamphetamine use continues to rise across the country, our results may gain greater relevance. Although our study was limited by the small number of deaths from psychostimulants, which may have limited our ability to detect statistically significant risk factors, to our knowledge, the study included the largest cohort of methamphetamine-related deaths in the United States.
We conclude that criminal justice populations should be warned about the risk of death because of psychostimulants, especially in the context of polydrug abuse and during the transition from prison to the community. Providing treatment for methamphetamine abuse to inmates, and continuing treatment upon release, may help prevent the trends illustrated by this study. Further research focused on understanding the mechanism of death caused by psychostimulants may allow for the development of an antidote to prevent death caused by acute intoxication. Educating people about the dangers of methamphetamine use and providing high-quality drug treatment programs are essential for prevention and treatment.
